Objective: To report our initial experience in treating renal nutcracker syndrome by retroperitoneal laparoscopic extravascular stenting. Patients and Methods: Two male patients, aged 13 and 16 years, were diagnosed with nutcracker syndrome and received retroperitoneal laparoscopic extravascular stent placement. The perioperative data were collected and evaluated. The follow-up was 10 and 18 months. Results: Both procedures were successful without obvious complications. Total operative time was 65 and 50 min, estimated blood loss was 110 and 70 ml, and postoperative hospital stay was 4 and 6 days. The symptom of gross hematuria ceased 3 and 6 days after surgery. Both patients had normal findings during follow-up. Conclusions: Treatment of nutcracker syndrome by retroperitoneal laparoscopic extravascular stent placement is a safe and feasible procedure, especially for youngsters in the period of physical development. Longer follow-up and further experience are needed to evaluate the efficacy of this procedure.

Keywords:
Retroperitoneal, Laparoscope, Nutcracker syndrome, Extravascular stent
1.
Ahmed K, Sampath R, Khan MS: Current trends in the diagnosis and management of renal nutcracker syndrome: a review. Eur J Vasc Endovasc Surg 2006;31:410-416.
2.
Shin JI, Lee JS, Kim MJ, et al: The prevalence, physical characteristics and diagnosis of nutcracker syndrome. Eur J Vasc Endovasc Surg 2006;32:335-336.
3.
Scultetus AH, Villavicencio JL, Gillespie DL: The nutcracker syndrome: its role in the pelvic venous disorders. J Vasc Surg 2001;34:812-819.
4.
Hohenfellner M, D'Elia G, Hampel C, et al: Transposition of the left renal vein for treatment of the nutcracker phenomenon: long-term follow-up. Urology 2002;59:354-357.
5.
Wang L, Yi L, Yang L, et al: Diagnosis and surgical treatment of nutcracker syndrome: a single-center experience. Urology 2009;73:871-876.
6.
Reed NR, Kalra M, Bower TC, et al: Left renal vein transposition for nutcracker syndrome. J Vasc Surg 2009;49:386-393.
7.
Chung BI, Gill IS: Laparoscopic splenorenal venous bypass for nutcracker syndrome. J Vasc Surg 2009;49:1319-1323.
8.
Gong XY, Zheng W, Du H, et al: Treatment of nutcracker syndrome with spermatic vein ligation and iliac vein anastomosis: case report of three case. Asian Pac J Trop Med 2012;5:923-924.
9.
Liu Y, Sun Y, Wu XJ, et al: Endovascular stent placement for the treatment of nutcracker syndrome. Int Urol Nephrol 2012;44:1097-1100.
10.
Menard MT: Nutcracker syndrome: when should it be treated and how? Perspect Vasc Surg Endovasc Ther 2009;21:117-124.
11.
Chen S, Zhang H, Tian L, et al: A stranger in the heart: LRV stent migration. Int Urol Nephrol 2009;41:427-430.
12.
Hartung O, Grisoli D, Boufi M, et al: Endovascular stenting in the treatment of pelvic vein congestion caused by nutcracker syndrome: lessons learned from the first five cases. J Vasc Surg 2005;42:275-280.
13.
Barnes RW, Fleisher HL III, Redman JF, et al: Mesoaortic compression of the left renal vein (the so-called nutcracker syndrome): repair by a new stenting procedure. J Vasc Surg 1988;8:415-421.
14.
Zhang Q, Zhang Y, Lou S, et al: Laparoscopic extravascular renal vein stent placement for nutcracker syndrome. J Endourol 2010;24:1631-1635.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.